Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer

IF 1.2 4区医学 Q3 PATHOLOGY

Medical Molecular Morphology Pub Date : 2024-04-15 DOI:10.1007/s00795-024-00386-z

Eriko Narusawa, Sasagu Kurozumi, Ayaka Katayama, Yukio Koibuchi, Akira Ogawa, Daisuke Takata, Shoko Tokuda, Sayaka Obayashi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe, Takaaki Fujii

{"title":"Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer","authors":"Eriko Narusawa, Sasagu Kurozumi, Ayaka Katayama, Yukio Koibuchi, Akira Ogawa, Daisuke Takata, Shoko Tokuda, Sayaka Obayashi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe, Takaaki Fujii","doi":"10.1007/s00795-024-00386-z","DOIUrl":null,"url":null,"abstract":"In some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known as HER2 heterogeneity. We investigated the clinicopathological features of patients with HER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess for HER2 heterogeneity, we used dual in situ hybridization slides. We evaluated the association between HER2 heterogeneity and clinicopathological factors such as rates of pathologic complete response (pCR) and of recurrence-free survival. Of the 39 patients, 15 (38.5%) had cancers with HER2 heterogeneity. The pCR rates were 13.3% among patients with HER2 heterogeneity and 20.8% among those with HER2 nonheterogeneity, but the difference was not significant. The recurrence-free survival rate was significantly lower in patients with HER2 heterogeneity than in those without (P = 0.025). HER2 heterogeneity is a significant predictor of poor prognosis in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy.","PeriodicalId":18338,"journal":{"name":"Medical Molecular Morphology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Molecular Morphology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00795-024-00386-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known as HER2 heterogeneity. We investigated the clinicopathological features of patients with HER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess for HER2 heterogeneity, we used dual in situ hybridization slides. We evaluated the association between HER2 heterogeneity and clinicopathological factors such as rates of pathologic complete response (pCR) and of recurrence-free survival. Of the 39 patients, 15 (38.5%) had cancers with HER2 heterogeneity. The pCR rates were 13.3% among patients with HER2 heterogeneity and 20.8% among those with HER2 nonheterogeneity, but the difference was not significant. The recurrence-free survival rate was significantly lower in patients with HER2 heterogeneity than in those without (P = 0.025). HER2 heterogeneity is a significant predictor of poor prognosis in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy.

Abstract Image

查看原文本刊更多论文

人类表皮生长因子 2 异质性作为三阴性乳腺癌预后因素的作用

在人类表皮生长因子2（HER2）阴性乳腺癌（包括三阴性乳腺癌）的某些病例中，HER2表达零星且强烈上调，这种情况被称为HER2异质性。我们研究了接受新辅助化疗的三阴性乳腺癌患者中 HER2 异质性患者的临床病理特征。39名接受过术前化疗的三阴性乳腺癌患者参与了这项研究。为了评估HER2异质性，我们使用了双原位杂交切片。我们评估了HER2异质性与病理完全反应率（pCR）和无复发生存率等临床病理因素之间的关联。在 39 名患者中，15 人（38.5%）的癌症存在 HER2 异质性。HER2异质性患者的pCR率为13.3%，HER2非异质性患者的pCR率为20.8%，但差异不显著。HER2异质性患者的无复发生存率明显低于非异质性患者（P = 0.025）。在接受新辅助化疗的三阴性乳腺癌患者中，HER2异质性是预后不良的重要预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Molecular Morphology 医学-病理学

CiteScore

2.90

自引率

5.60%

发文量

审稿时长

>12 weeks

期刊介绍： Medical Molecular Morphology is an international forum for researchers in both basic and clinical medicine to present and discuss new research on the structural mechanisms and the processes of health and disease at the molecular level. The structures of molecules, organelles, cells, tissues, and organs determine their normal function. Disease is thus best understood in terms of structural changes in these different levels of biological organization, especially in molecules and molecular interactions as well as the cellular localization of chemical components. Medical Molecular Morphology welcomes articles on basic or clinical research in the fields of cell biology, molecular biology, and medical, veterinary, and dental sciences using techniques for structural research such as electron microscopy, confocal laser scanning microscopy, enzyme histochemistry, immunohistochemistry, radioautography, X-ray microanalysis, and in situ hybridization. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.